An Open Label Access Study For Subjects Who Completed A1481156
Status:
No longer available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to provide sildenafil therapy to subjects who have completed the
A1481156 study for the treatment of Pulmonary Arterial Hypertension (PAH) in India and are
judged by the Investigator to derive clinical benefit from continued treatment with
sildenafil citrate. Sildenafil citrate will be supplied for the treatment of Pulmonary
Arterial Hypertension (PAH) until the subject continues to derive benefits from the
treatment. The treating physicians (and the sponsor) will be responsible for reporting
serious adverse events.
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.